Welcome to our dedicated page for ChromaDex Corporation news (Ticker: CDXC), a resource for investors and traders seeking the latest updates and insights on ChromaDex Corporation stock.
ChromaDex Corporation (NASDAQ: CDXC) is a pioneering global nutraceutical company dedicated to enhancing healthy aging through scientific advancements. The company's mission revolves around improving the way people age by focusing on the potential of nicotinamide adenine dinucleotide (NAD+), a critical coenzyme in metabolic processes that declines with age.
ChromaDex's team of scientists partners with renowned universities and research institutions worldwide to explore and develop innovative, science-based ingredients. Their flagship product, Tru Niagen®, is a supplement that features Niagen® (nicotinamide riboside), an NAD+ precursor aimed at promoting better aging. Alongside Tru Niagen®, ChromaDex's product portfolio includes PteroPure® (pterostilbene), PureEnergy® (a caffeine-pterostilbene co-crystal), and Anthorigin™ (anthocyanins).
The company operates through three primary segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The majority of ChromaDex's revenue is generated from its Consumer Products segment, driven by the popularity and efficacy of Tru Niagen®.
ChromaDex's commitment to scientific research is evident in its numerous collaborations with academic institutions. These partnerships aim to uncover the full potential of NAD+ and other beneficial compounds to develop products that support health and longevity.
The company's stock is publicly traded on NASDAQ under the symbol CDXC. For more information on ChromaDex, visit their website at www.chromadex.com, follow them on Twitter @chromadex, or like their Facebook page here.
Recent Achievements and Current Projects:
- Continued research and development into NAD+ and its related compounds.
- Expansion of Tru Niagen® into new markets globally.
- Ongoing partnerships with leading universities and research institutions.
- Innovative new product launches aimed at further promoting healthy aging.
ChromaDex Corp. (NASDAQ:CDXC) has appointed Ozan Pamir as Chief Financial Officer, effective October 21, 2024. Mr. Pamir will oversee all corporate finance matters, including accounting, strategic financial planning, and investor relations, reporting directly to CEO Rob Fried. Prior to joining ChromaDex, Pamir served as CFO of 180 Life Sciences, where he played a key role in the company's NASDAQ listing and managed funding rounds. He has also worked with two early-stage biotech companies as CFO and board member, and was previously VP of Investment Banking at a leading independent investment bank. Mr. Pamir holds an Economics and Finance degree from McGill University and is a CFA Charterholder.
ChromaDex Corp. (NASDAQ:CDXC) has announced the expansion of its pharmaceutical-grade Niagen® (nicotinamide riboside chloride) IV and injection offerings to 14 additional leading wellness clinics across the United States. This follows the successful debut of quantities in select clinics last month. Wells Pharma of Houston, a U.S. FDA-registered 503B outsourcing facility, will compound and distribute the product, branded as Niagen+, exclusively to these clinics with a prescription.
Niagen, ChromaDex's flagship ingredient, is clinically proven to elevate NAD+ levels, important for cellular health. The IV and injection formulations offer rapid and efficient delivery, outperforming NAD+ IV in a pilot clinical study with superior tolerability, 75% shorter infusion time, and a significant 20% increase in whole blood NAD+ levels. Several clinic directors have expressed excitement about the potential of Niagen IV in health optimization and longevity treatments.
ChromaDex Corp. (NASDAQ:CDXC) celebrates its 25th anniversary as a pioneer in NAD+ research and healthy aging solutions. Founded in 1999, ChromaDex has evolved from an analytical testing company to a leader in developing proprietary ingredients for dietary supplements. The company's flagship product, Tru Niagen®, is the top NAD+ supplement for healthy aging in the U.S., with over 8 million bottles sold.
Key achievements include:
- Licensing patents for Dr. Charles Brenner's nicotinamide riboside (NR) research in 2012
- Launching Niagen®, the first patented form of NR, in 2013
- Introducing pharmaceutical-grade Niagen+™ for intravenous therapy in 2024
- Establishing the ChromaDex External Research Program (CERP™), which has facilitated over 275 research agreements globally
- Building a portfolio of 90+ patents related to NAD+ precursors
To mark this milestone, ChromaDex is offering a 25% discount on lifelong Tru Niagen® subscriptions and one-time purchases until September 12, 2024.
ChromaDex Corp. (NASDAQ:CDXC), a leader in NAD+ research and healthy aging, will participate in Renmark's Virtual Non-Deal Roadshow Series on Thursday, August 29, 2024, at 2:00 PM EDT. The event will feature a presentation by key executives, including CEO Rob Fried, Interim CFO James Lee, and VP Finance Wesley Yu.
The live presentation will cover ChromaDex's latest investor information, followed by a Q&A session. While live event registration may be , a replay will be available on the company's investor website. Interested parties can register for the event using the provided link, and are advised to use the latest version of Google Chrome for optimal connectivity.
This virtual roadshow offers an opportunity for stakeholders, investors, and followers to gain insights into ChromaDex's current initiatives and future prospects in the field of healthy aging and NAD+ research.
ChromaDex Corp. (NASDAQ:CDXC) has secured U.S. Patent number 10,000,520 C1 for the composition of matter of salt forms of NMNH (dihydronicotinamide mononucleotide), a precursor to NAD+. This patent, co-owned with Queen's University Belfast, grants ChromaDex exclusive rights to the disodium salt form of NMNH. The company now has over 80 patents related to NAD+ precursors, including its flagship ingredient Niagen® (nicotinamide riboside).
NMNH is distinct from NMN, which was banned as a dietary supplement by the FDA in 2022. While NMNH has shown promise in preclinical studies, further research is needed to determine its oral bioavailability and safety as a dietary supplement. Currently, NMNH's legal status as a dietary supplement is questionable due to lack of proper FDA notification as a new dietary ingredient (NDI).
ChromaDex Corp. (NASDAQ:CDXC) reported strong Q2 2024 financial results, with total net sales of $22.7 million, up 12% year-over-year. Tru Niagen® sales reached $18.6 million, a 10% increase. The company achieved a gross margin of 60.2% and reduced operating expenses by $0.7 million compared to the prior year quarter. ChromaDex reported an approximately breakeven net loss and positive Adjusted EBITDA of $1.6 million.
Key developments include receiving U.S. FDA Orphan Drug Designation for nicotinamide riboside chloride to treat Ataxia Telangiectasia, and launching Niagen+, a pharmaceutical-grade product line. The company also introduced Niagen+ NAD+ Test Kits for healthcare practitioners. For the full year 2024, ChromaDex expects 10-15% revenue growth and slightly improved gross margins.
ChromaDex Corp. (NASDAQ:CDXC), a leader in NAD+ research and healthy aging, announces its participation in Canaccord Genuity's 44th Annual Growth Conference from August 13-15, 2024, in Boston. CEO Rob Fried and Interim CFO James Lee will present on August 14 and conduct one-on-one meetings throughout the event.
This prestigious conference, a 44-year cornerstone for industry leaders and investors, provides ChromaDex an opportunity to showcase its latest developments, strategic initiatives, and growth prospects. Interested parties can arrange meetings through the conference website or their CG representative.
ChromaDex's involvement underscores its commitment to engaging with investors and industry experts, potentially impacting its market position and future growth strategies in the healthy aging sector.
ChromaDex Corp. (NASDAQ:CDXC), a leader in NAD+ research and healthy aging, has announced its Q2 2024 financial results conference call. The call is scheduled for Wednesday, August 7, 2024, at 4:30 p.m. ET. Financial results will be released via press release after market close on the same day. Investors can join the call using the toll-free number 1-888-596-4144 (Conference ID: 8584242) or via webcast. Management will discuss Q2 results and provide a general business update. A replay will be available until August 14, 2024. This event offers investors an opportunity to gain insights into ChromaDex's financial performance and future outlook.
ChromaDex Corp. (NASDAQ:CDXC) has launched the Niagen+ NAD+ Test Kit, exclusively available through its healthcare practitioner (HCP) channel. This innovative kit allows practitioners to measure patient blood NAD+ levels, enabling more personalized protocols using ChromaDex's NAD+-boosting products, Tru Niagen® and Niagen+.
The test kit features advanced dried blood spot (DBS) assay technology, ensuring NAD+ sample stability during transport. Analysis is conducted using high-resolution liquid chromatography/tandem mass spectrometry (LC-MS/MS) at a CLIA and CAP accredited laboratory. Results are available to both patients and doctors in about two weeks through the 1health platform.
This launch represents a significant advancement in NAD+ therapy, allowing practitioners to track NAD+ changes over time and create more effective patient protocols.
ChromaDex Corp. (NASDAQ:CDXC) has appointed Carlos Lopez as Senior Vice President, General Counsel, effective July 22, 2024. Lopez, a distinguished legal professional with expertise in the dietary supplements industry, will oversee the organization's legal function, including corporate governance, securities, intellectual property, and litigation. He will report directly to CEO Rob Fried.
Prior to joining ChromaDex, Lopez served as Vice President, General Counsel at The Vitamin Shoppe and has been on the board of The Natural Products Association. CEO Rob Fried expressed confidence in Lopez's expertise to help achieve ChromaDex's ambitious plans. Lopez stated his excitement to join ChromaDex, recognizing it as the gold-standard company pioneering NAD+ research and innovation.
FAQ
What is the current stock price of ChromaDex Corporation (CDXC)?
What is the market cap of ChromaDex Corporation (CDXC)?
What is ChromaDex Corporation's main focus?
What is Tru Niagen®?
How does ChromaDex generate most of its revenue?
On which stock exchange is ChromaDex traded?
What are some of ChromaDex's other products?
Who are ChromaDex's research partners?
What is NAD+?
Where can I find more information about ChromaDex?
Does ChromaDex offer services apart from consumer products?
How is ChromaDex contributing to healthy aging research?
